Skip To Main Content
Hualin Feng on Muck Rack

Hualin Feng

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hualin

Contact Hualin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of GC001: an oncolytic vaccinia virus expressing STRIP1 shRNA

|
By Gongchu Li, Gaohui Jiang, Wei Kong Pang, Ruikang Liu, Huiwei Zhang, Jili Zhu, Jiawei Su, Borong Zhu, Ying Zhu, Guohui Zhang, Weizhe Xu, Kan Chen, Yanrong Zhou, Li Sun, Zhe Qu, Xin Wang, Zheqi Cai, Jianlei Yu, Hualin Feng, Dongsheng Pan, Xingchao Geng, Yunshan Ning
| Nature Verified
Abstract GC001, a thymidine kinase deleted oncolytic vaccinia virus expressing striatin-interacting protein 1 (STRIP1) shRNA, has been approved by National Medical Products Administration (NMPA) of China to enter phase I clinical trial in 2023. Anti-tumour efficacy of GC001 across multiple cancer types was evaluated in mouse xenograft models. Anti-tumour immune responses were investigated in immunocompetent or humanised cancer mouse model.
Open in Who Shared Issue with article?
See all 1 articles